Sales of contact lenses increased by 22 percent to $51.2 million in the second quarter for Valeant Pharmaceuticals, the parent company of Bausch & Lomb. They were up by 19 percent in the first six months of this year, driven by BioTrue, which has been launched also in China. Valeant's total revenues grew by 34 percent to $2.7 billion in the second quarter. Operating income declined by 3.8 percent to $341.5 million. Net losses of $53.0 million stood against net income of $125.8 million in the year-ago period.